title: Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry.
abstract: BACKGROUND
  Quantification of serum tumor markers plays an important role in determining whether patients treated for cancer require further therapy. Whereas large-scale proteomic efforts aim to identify novel tumor markers to facilitate early detection, optimization of methods for quantifying known tumor markers offers another approach to improving management of malignancies. For example, immunoassays used in clinical practice to measure established tumor markers suffer from potential interference from endogenous immunoglobulins and imperfect concordance across platforms-problems that also plague many other immunoassays. To address these important limitations, this study used peptide immunoaffinity enrichment in concert with liquid chromatography-tandem mass spectrometry (LC-MS/MS) to quantify thyroglobulin, a well-characterized tumor marker.
  
  
  METHODS
  We identified 3 peptides in tryptic digests of thyroglobulin that were detected at low concentrations by tandem mass spectrometry, raised polyclonal antibodies to those peptides, and used the antibodies to extract the 3 corresponding peptides from tryptic digests of human serum. We quantified each endogenous peptide using LC-MS/MS and multiple reaction monitoring with external calibrators.
  
  
  RESULTS
  The detection limit for endogenous thyroglobulin in serum was 2.6 microg/L (4 pmol/L). Direct comparison with immunoassay revealed good correlation (r(2) = 0.81).
  
  
  CONCLUSIONS
  Immunoaffinity peptide enrichment-tandem mass spectrometry can detect tryptic peptides of thyroglobulin at picomolar concentrations while also digesting the endogenous immunoglobulins that can potentially interfere with traditional immunoassays. Our observations suggest a general analytical strategy for using immunoaffinity isolation together with tandem mass spectrometry to quantify tumor antigens and other low-abundance proteins in human serum.
authors.affiliation: Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA. ahoof@u.washington.edu
authors.forename: Andrew N
authors.initials: AN
authors.lastname: Hoofnagle
authors.forename: Jessica O
authors.initials: JO
authors.lastname: Becker
authors.forename: Mark H
authors.initials: MH
authors.lastname: Wener
authors.forename: Jay W
authors.initials: JW
authors.lastname: Heinecke
mesh_terms: D000595:Amino Acid Sequence; D002846:Chromatography, Affinity / Q000379:methods*; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D006801:Humans; D007118:Immunoassay; D010446:Peptide Fragments / Q000097:blood / Q000737:chemistry / Q000302:isolation & purification; D010449:Peptide Mapping; D012015:Reference Standards; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D053719:Tandem Mass Spectrometry / Q000379:methods*; D013954:Thyroglobulin / Q000097:blood* / Q000737:chemistry / Q000302:isolation & purification
chemical_list: D010446:Peptide Fragments; D013954:Thyroglobulin
references.citation: J Clin Endocrinol Metab. 2003 Jul;88(7):3069-74
references.pmid: 12843145
references.citation: Clin Chem. 2007 Aug;53(8):1462-9
references.pmid: 17586588
references.citation: Eur J Nucl Med Mol Imaging. 2002 Aug;29 Suppl 2:S492-6
references.pmid: 12192551
references.citation: Proteomics Clin Appl. 2007 Jan 1;1(1):73-88
references.pmid: 20204147
references.citation: Clin Immunol Immunopathol. 1985 Nov;37(2):154-62
references.pmid: 3930112
references.citation: J Proteome Res. 2004 Mar-Apr;3(2):235-44
references.pmid: 15113099
references.citation: Nat Biotechnol. 2006 Aug;24(8):971-83
references.pmid: 16900146
references.citation: J Clin Endocrinol Metab. 2004 Aug;89(8):3702-4
references.pmid: 15292292
references.citation: Clin Chem. 1996 May;42(5):661-3
references.pmid: 8653888
references.citation: J Clin Endocrinol Metab. 1998 Apr;83(4):1121-7
references.pmid: 9543128
references.citation: Clin Chem. 2007 May;53(5):810-2
references.pmid: 17468407
references.citation: Clin Chem. 2005 Apr;51(4):729-34
references.pmid: 15695326
references.citation: Clin Lab Med. 2004 Mar;24(1):29-47
references.pmid: 15157556
references.citation: Clin Chem. 1996 Oct;42(10):1676-82
references.pmid: 8855153
references.citation: Am J Clin Pathol. 2006 May;125(5):752-7
references.pmid: 16707378
references.citation: Ann Biol Clin (Paris). 1996;54(10-11):343-8
references.pmid: 9092301
references.citation: Methods Mol Biol. 2000;149:III-IV, 1-413
references.pmid: 11028258
references.citation: Arch Biochem Biophys. 1996 Mar 1;327(1):61-70
references.pmid: 8615697
references.citation: Thyroid. 2001 Sep;11(9):819-24
references.pmid: 11575850
references.citation: Clin Chem. 2007 Apr;53(4):673-8
references.pmid: 17317883
references.citation: Proteomics. 2004 Apr;4(4):1175-86
references.pmid: 15048997
references.citation: J Clin Endocrinol Metab. 2005 Sep;90(9):5047-57
references.pmid: 15972576
references.citation: J Biol Chem. 1997 Jan 3;272(1):639-46
references.pmid: 8995307
references.citation: Clin Endocrinol (Oxf). 2003 Feb;58(2):138-40
references.pmid: 12580927
references.citation: Nucl Med Commun. 2006 Jul;27(7):567-72
references.pmid: 16794517
references.citation: J Proteome Res. 2007 Oct;6(10):3962-75
references.pmid: 17711321
references.citation: Rev Endocr Metab Disord. 2000 Jan;1(1-2):69-77
references.pmid: 11704994
references.citation: Mol Cell Proteomics. 2007 Dec;6(12):2212-29
references.pmid: 17939991
references.citation: J Biol Chem. 1987 Jul 25;262(21):10304-14
references.pmid: 2440862